首页> Oncoscience> Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?

导出 LinkOut

翻译打印收藏纠错

第一作者： Maria Rosa,Cappelletti

第一单位： U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.

作者： Maria Rosa,Cappelletti ^[1] ; Letizia,Gnetti ^[2] ; Daniele,Santini ^[3] ; Daniele,Spada ^[1] ; Stephen B,Fox ^[4] ; Daniele,Generali ^[1]

作者单位： U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy. ^[1] Department of Onco-Haematological and Internal Medicine, Section of Pathology University of Parma, Parma, Italy. ^[2] University Campus Bio-Medico Roma, Oncologia Medica, Roma, Italy. ^[3] Department of Anatomical Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. ^[4]

关键词 FGFR inhibitors FGFR2 endometrial cancer everolimus

DOI 10.18632/oncoscience.168

PMID 26244161

发布时间 2020-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Oncoscience

2015年2卷6期

567-9页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Oncoscience

2015年2卷6期

567-9页

检索历史清除

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?

Oncoscience

相似文献

同项目论文

Oncoscience

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?

Oncoscience

相似文献

同项目论文

Oncoscience

相关期刊

检索历史清除